Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager

Newron Pharmaceuticals SpA

SIX:NWRN

Watchlist

Dividends

Discount Rate

Price: 7.61 CHF 2.15%

Market Cap: 145m CHF

Have any thoughts about
Newron Pharmaceuticals SpA?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Estee Lauder Companies Inc NYSE:EL	Consumer products
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Church & Dwight Co Inc NYSE:CHD	Consumer products
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	American Express Co NYSE:AXP	Financial Services
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Target Corp NYSE:TGT	Retail
US	Walt Disney Co NYSE:DIS	Media
US	Mueller Industries Inc NYSE:MLI	Machinery
US	PayPal Holdings Inc NASDAQ:PYPL	Technology

Add Price Alert

Price Target:

Last Price: 7.61 CHF

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

NWRN Alert

Newron Pharmaceuticals SpA

7.61

+0.16 (+2.15%)

52 Week Range	4.23 10.96
Price Target

We'll email you a reminder when the closing price reaches CHF.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Estee Lauder Companies Inc NYSE:EL	US
	Exxon Mobil Corp NYSE:XOM	US
	Church & Dwight Co Inc NYSE:CHD	US
	Pfizer Inc NYSE:PFE	US
	American Express Co NYSE:AXP	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Target Corp NYSE:TGT	US
	Walt Disney Co NYSE:DIS	US
	Mueller Industries Inc NYSE:MLI	US
	PayPal Holdings Inc NASDAQ:PYPL	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Newron Pharmaceuticals SpA

What unique competitive advantages
does Newron Pharmaceuticals SpA hold over its rivals?

What risks and challenges
does Newron Pharmaceuticals SpA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Newron Pharmaceuticals SpA.

What unique competitive advantages
does Newron Pharmaceuticals SpA hold over its rivals?

What risks and challenges
does Newron Pharmaceuticals SpA face in the near future?

Has there been any significant insider trading activity
in Newron Pharmaceuticals SpA recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Newron Pharmaceuticals SpA.

Provide P/S
for Newron Pharmaceuticals SpA.

Provide P/E
for Newron Pharmaceuticals SpA.

Provide P/OCF
for Newron Pharmaceuticals SpA.

Provide P/FCFE
for Newron Pharmaceuticals SpA.

Provide P/B
for Newron Pharmaceuticals SpA.

Provide EV/S
for Newron Pharmaceuticals SpA.

Provide EV/GP
for Newron Pharmaceuticals SpA.

Provide EV/EBITDA
for Newron Pharmaceuticals SpA.

Provide EV/EBIT
for Newron Pharmaceuticals SpA.

Provide EV/OCF
for Newron Pharmaceuticals SpA.

Provide EV/FCFF
for Newron Pharmaceuticals SpA.

Provide EV/IC
for Newron Pharmaceuticals SpA.

Show me price targets
for Newron Pharmaceuticals SpA made by professional analysts.

What are the Revenue projections
for Newron Pharmaceuticals SpA?

How accurate were the past Revenue estimates
for Newron Pharmaceuticals SpA?

What are the Net Income projections
for Newron Pharmaceuticals SpA?

How accurate were the past Net Income estimates
for Newron Pharmaceuticals SpA?

What are the EPS projections
for Newron Pharmaceuticals SpA?

How accurate were the past EPS estimates
for Newron Pharmaceuticals SpA?

What are the EBIT projections
for Newron Pharmaceuticals SpA?

How accurate were the past EBIT estimates
for Newron Pharmaceuticals SpA?

Compare the revenue forecasts
for Newron Pharmaceuticals SpA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Newron Pharmaceuticals SpA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Newron Pharmaceuticals SpA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Newron Pharmaceuticals SpA compared to its peers.

Compare the P/E ratios
of Newron Pharmaceuticals SpA against its peers.

Discuss the investment returns and shareholder value creation
comparing Newron Pharmaceuticals SpA with its peers.

Analyze the financial leverage
of Newron Pharmaceuticals SpA compared to its main competitors.

Show all profitability ratios
for Newron Pharmaceuticals SpA.

Provide ROE
for Newron Pharmaceuticals SpA.

Provide ROA
for Newron Pharmaceuticals SpA.

Provide ROIC
for Newron Pharmaceuticals SpA.

Provide ROCE
for Newron Pharmaceuticals SpA.

Provide Gross Margin
for Newron Pharmaceuticals SpA.

Provide Operating Margin
for Newron Pharmaceuticals SpA.

Provide Net Margin
for Newron Pharmaceuticals SpA.

Provide FCF Margin
for Newron Pharmaceuticals SpA.

Show all solvency ratios
for Newron Pharmaceuticals SpA.

Provide D/E Ratio
for Newron Pharmaceuticals SpA.

Provide D/A Ratio
for Newron Pharmaceuticals SpA.

Provide Interest Coverage Ratio
for Newron Pharmaceuticals SpA.

Provide Altman Z-Score Ratio
for Newron Pharmaceuticals SpA.

Provide Quick Ratio
for Newron Pharmaceuticals SpA.

Provide Current Ratio
for Newron Pharmaceuticals SpA.

Provide Cash Ratio
for Newron Pharmaceuticals SpA.

What is the historical Revenue growth
over the last 5 years for Newron Pharmaceuticals SpA?

What is the historical Net Income growth
over the last 5 years for Newron Pharmaceuticals SpA?

What is the current Free Cash Flow
of Newron Pharmaceuticals SpA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Newron Pharmaceuticals SpA.

NWRN

Balance Sheet

Total Current Liabilities

Newron Pharmaceuticals SpA
Total Current Liabilities

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

Adjust for Inflation

Newron Pharmaceuticals SpA
Total Current Liabilities Peer Comparison

Comparables:

REC

PRL

FCM

SHE

Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors

Company		Total Current Liabilities	CAGR 3Y	CAGR 5Y	CAGR 10Y
	Newron Pharmaceuticals SpA SIX:NWRN	Total Current Liabilities €28.9m	CAGR 3-Years 61%	CAGR 5-Years 46%	CAGR 10-Years N/A
	Recordati Industria Chimica e Farmaceutica SpA MIL:REC	Total Current Liabilities €887.2m	CAGR 3-Years 15%	CAGR 5-Years 17%	CAGR 10-Years 11%
P	Pierrel SpA MIL:PRL	Total Current Liabilities €19.9m	CAGR 3-Years 29%	CAGR 5-Years 15%	CAGR 10-Years -10%
	Friulchem SpA MIL:FCM	Total Current Liabilities €17.5m	CAGR 3-Years 46%	CAGR 5-Years 37%	CAGR 10-Years N/A
	Shedir Pharma Srl Unipersonale MIL:SHE	Total Current Liabilities €14.4m	CAGR 3-Years 5%	CAGR 5-Years -8%	CAGR 10-Years N/A

What is Newron Pharmaceuticals SpA's Total Current Liabilities?

Total Current Liabilities
28.9m EUR

Based on the financial report for Dec 31, 2023, Newron Pharmaceuticals SpA's Total Current Liabilities amounts to 28.9m EUR.

What is Newron Pharmaceuticals SpA's Total Current Liabilities growth rate?

Total Current Liabilities CAGR 5Y
46%

Over the last year, the Total Current Liabilities growth was 474%. The average annual Total Current Liabilities growth rates for Newron Pharmaceuticals SpA have been 61% over the past three years , 46% over the past five years .

Newron Pharmaceuticals SpA
SIX:NWRN

Newron Pharmaceuticals SpA
Total Current Liabilities

Newron Pharmaceuticals SpA
Total Current Liabilities Peer Comparison

Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors

See Also

What is Newron Pharmaceuticals SpA's Total Current Liabilities?

Total Current Liabilities
28.9m EUR

What is Newron Pharmaceuticals SpA's Total Current Liabilities growth rate?

Total Current Liabilities CAGR 5Y
46%

Company

Help

Tools

Stocks

Newron Pharmaceuticals SpA SIX:NWRN

Newron Pharmaceuticals SpA Total Current Liabilities

Newron Pharmaceuticals SpA Total Current Liabilities Peer Comparison

Competitive Total Current Liabilities Analysis Latest Figures & CAGR of Competitors

See Also

What is Newron Pharmaceuticals SpA's Total Current Liabilities? Total Current Liabilities 28.9m EUR

What is Newron Pharmaceuticals SpA's Total Current Liabilities growth rate? Total Current Liabilities CAGR 5Y 46%

Company

Help

Tools

Stocks

Newron Pharmaceuticals SpA
SIX:NWRN

Newron Pharmaceuticals SpA
Total Current Liabilities

Newron Pharmaceuticals SpA
Total Current Liabilities Peer Comparison

Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors

What is Newron Pharmaceuticals SpA's Total Current Liabilities?

Total Current Liabilities
28.9m EUR

What is Newron Pharmaceuticals SpA's Total Current Liabilities growth rate?

Total Current Liabilities CAGR 5Y
46%